BioLineRx (BLRX) Total Non-Current Liabilities (2011 - 2025)

BioLineRx's Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $5.4 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 45.84% year-over-year to $5.4 million in Q4 2025; TTM through Dec 2025 was $5.4 million, a 45.84% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, down 45.84% from the prior year.
• Total Non-Current Liabilities slipped to $5.4 million in Q4 2025 per BLRX's latest filing, from $6.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $25.4 million in Q2 2023 and bottomed at $1.6 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $8.3 million (2023), against an average of $11.2 million.
• Across the five-year window, Total Non-Current Liabilities tumbled 78.22% in 2022 and jumped 1452.87% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $3.6 million in 2021, then surged by 314.62% to $14.9 million in 2022, then sank by 46.73% to $7.9 million in 2023, then increased by 26.79% to $10.0 million in 2024, then slumped by 45.84% to $5.4 million in 2025.
• Per Business Quant, the three latest BLRX Total Non-Current Liabilities figures stand at $5.4 million (Q4 2025), $6.6 million (Q3 2025), and $7.7 million (Q2 2025).